Scinai Immunotherapeutics (SCNI) Net Income (2014 - 2026)
Scinai Immunotherapeutics (SCNI) posted Net Income of -$2.5 million for Q1 2026, down 12.39% sequentially from -$2.2 million in Q2 2025, and down 57.33% YoY from -$5.8 million in Q1 2025.
Scinai Immunotherapeutics (SCNI) Net Income (2014 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Net Income for 13 years, with the latest figure at -$2.5 million in Q1 2026.
- Quarterly Net Income fell 57.33% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.2 million (down 182.27% YoY) and the FY2025 annual result came in at -$38.3 million, down 18.32% from the prior year.
- Net Income eased to -$2.5 million in Q1 2026 per SCNI's latest filing, from -$2.2 million in the prior quarter.
- Over five years, Net Income peaked at $10.5 million in Q3 2024 and troughed at -$22.6 million in Q4 2022.
- A 5-year average of -$1.9 million and a median of -$1.9 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income tumbled 614.25% in 2022, then jumped 287.17% in 2023.
- Over 5 years, Net Income stood at -$22.6 million in 2022, then soared by 75.01% to -$5.6 million in 2023, then surged by 35.47% to -$3.6 million in 2024, then surged by 39.63% to -$2.2 million in 2025, then slipped by 12.39% to -$2.5 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$2.5 million, -$2.2 million, and -$1.6 million for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | -2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.47 Mn |
| Jun 30, 2025 | -2.20 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Dec 31, 2024 | -3.64 Mn |
| Sep 30, 2024 | 10.46 Mn |
| Jun 30, 2024 | 2.32 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | -5.64 Mn |
| Sep 30, 2023 | -11.45 Mn |
| Jun 30, 2023 | 3.76 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | -22.55 Mn |
| Sep 30, 2022 | -6.14 Mn |
| Jun 30, 2022 | 6.91 Mn |
| Mar 31, 2022 | -1.88 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | -9.05 Mn |
| Jun 30, 2021 | -11.99 Mn |
| Mar 31, 2021 | -2.46 Mn |
| Dec 31, 2020 | -14.10 Mn |